Impact of autumn 2023 and 2024 COVID-19 vaccination in preventing COVID-19 related hospitalisations and deaths in seven EU/EEA countries: a VEBIS-EHR network study

Within the VEBIS-EHR project, monthly vaccine effectiveness (VE) of COVID-19 vaccines is routinely estimated across EU/EEA countries. While VE quantifies direct protection, it does not capture the overall population benefit of vaccination campaigns in terms of severe outcomes prevented.

Aim

To estimate the impact of the 2023 and 2024 autumn COVID-19 vaccination campaigns in adults aged ≥65 years.

Methods

We conducted a retrospective cohort study using electronic health records data from Belgium, Denmark, Italy, Navarre (Spain), Portugal, Norway and Sweden. Weekly numbers of averted COVID-19-related hospitalisations and deaths during the 12 months following each campaign were estimated using observed COVID-19-related events, vaccine coverage (VC) and interpolated weekly VE.

Results

Across participating countries/regions, among adults aged ≥65 years, the 2023 autumn vaccination campaign averted approximately 6,200 hospitalisations (prevented fraction [PF] 10%) compared with 2,200 (PF 12%) in 2024. Among those aged ≥80 years, the number of averted COVID-19-related deaths was 811 (PF 13%) for the 2023 campaign and 156 (PF 12%) for the 2024 campaign. Impact varied across countries, reflecting differences in VC, vaccination timing and outcome occurrence.

Conclusion

The 2023 and 2024 autumn vaccination campaigns resulted in substantially different numbers of averted COVID-19-related hospitalisations and deaths among older adults, with fewer events averted in 2024. These findings highlight that the impact of vaccination programmes depends not only on VC and VE but also on alignment between vaccination timing and periods of increased viral circulation.